Roche To Improve Real-World Cancer Data Extraction With Flatiron Buy
Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.
You may also be interested in...
Roche Diagnostics Sees Data Sourcing, AI and Partnerships As Paving The Way to Personalized Health Care, But Challenges Remain
Two Roche Diagnostics executives outlined the company's vision toward personalized health care. Machine learning, partnerships and data sourcing are key.
Brexit, the "Implant Files" and the new EU regulations – however large they loom at present, they will in time be seen as mere tactical challenges for a global medtech industry working hard to ensure that it is ready for the massive health-care delivery and service-oriented changes to come. Preparing for the future and maximizing current market penetration – in the UK, the EU and beyond – were key themes at UK HealthTech 2018, held in Cardiff, Wales.
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.